Foghorn Therapeutics Inc. Proceeds from Sale and Maturity of Marketable Securities
Foghorn Therapeutics Inc. (FHTX) reported Proceeds from Sale and Maturity of Marketable Securities of $83.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-06
- Foghorn Therapeutics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $34.17M, a 55.04% decline year-over-year.
- Foghorn Therapeutics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $49.22M, a 38.90% decline year-over-year.
- Foghorn Therapeutics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $47.21M, a 24.36% decline year-over-year.
- Foghorn Therapeutics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $39.58M, a 37.63% decline year-over-year.
- Foghorn Therapeutics Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $243.34M, a 4.67% increase from fiscal 2024.
- Foghorn Therapeutics Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $232.47M, a 5.87% increase from fiscal 2023.
- Foghorn Therapeutics Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $219.57M, a 32.09% increase from fiscal 2022.
- Foghorn Therapeutics Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $166.23M, a 19.19% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $83.39M 10-Q · filed 2026-08-06 | $130.60M derived: sum of 3 quarters · filed 2026-08-06 | $170.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $49.22M 10-Q · filed 2026-05-07 | $96.43M derived: sum of 2 quarters · filed 2026-05-07 | $136.01M derived: sum of 3 quarters · filed 2026-05-07 | $212.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $47.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $86.79M derived: sum of 2 quarters · filed 2026-03-11 | $162.78M derived: sum of 3 quarters · filed 2026-08-06 | $243.34M 10-K · filed 2026-03-11 |
| 2025-09-30 | $39.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $115.57M derived: sum of 2 quarters · filed 2026-08-06 | $196.12M 10-Q · filed 2025-11-05 | $258.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $76.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $156.55M 10-Q · filed 2026-08-06 | $218.97M derived: sum of 3 quarters · filed 2026-08-06 | $282.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $80.55M 10-Q · filed 2026-05-07 | $142.97M derived: sum of 2 quarters · filed 2026-05-07 | $206.42M derived: sum of 3 quarters · filed 2026-05-07 | $254.57M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $62.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $125.87M derived: sum of 2 quarters · filed 2026-03-11 | $174.01M derived: sum of 3 quarters · filed 2026-03-11 | $232.47M 10-K · filed 2026-03-11 |
| 2024-09-30 | $63.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $111.59M derived: sum of 2 quarters · filed 2025-11-05 | $170.05M 10-Q · filed 2025-11-05 | $214.32M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $48.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $106.61M 10-Q · filed 2025-08-05 | $150.87M derived: sum of 3 quarters · filed 2025-08-05 | $193.23M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $58.46M 10-Q · filed 2025-05-14 | $102.72M derived: sum of 2 quarters · filed 2025-05-14 | $145.09M derived: sum of 3 quarters · filed 2025-05-14 | $221.66M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $44.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $86.63M derived: sum of 2 quarters · filed 2025-03-06 | $163.20M derived: sum of 3 quarters · filed 2025-03-06 | $219.57M 10-K · filed 2025-03-06 |
| 2023-09-30 | $42.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $118.94M derived: sum of 2 quarters · filed 2024-11-04 | $175.31M 10-Q · filed 2024-11-04 | $213.41M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $76.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $132.95M 10-Q · filed 2024-08-08 | $171.05M derived: sum of 3 quarters · filed 2024-08-08 | $227.05M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $56.37M 10-Q · filed 2024-05-06 | $94.47M derived: sum of 2 quarters · filed 2024-05-06 | $150.47M derived: sum of 3 quarters · filed 2024-05-06 | $169.47M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $38.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $94.10M derived: sum of 2 quarters · filed 2024-03-07 | $113.10M derived: sum of 3 quarters · filed 2024-03-07 | $166.23M 10-K · filed 2024-03-07 |
| 2022-09-30 | $56.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $75.00M derived: sum of 2 quarters · filed 2023-11-02 | $128.13M 10-Q · filed 2023-11-02 | $148.13M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $72.13M 10-Q · filed 2023-08-04 | $92.13M derived: sum of 3 quarters · filed 2023-08-04 | $92.13M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $53.13M 10-Q · filed 2023-05-08 | $73.13M derived: sum of 2 quarters · filed 2023-05-08 | $73.13M derived: sum of 3 quarters · filed 2023-05-08 | $167.60M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $20.00M derived: sum of 2 quarters · filed 2023-03-09 | $114.47M derived: sum of 3 quarters · filed 2023-03-09 | $139.47M 10-K · filed 2023-03-09 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $94.47M derived: sum of 2 quarters · filed 2022-11-08 | $119.47M 10-Q · filed 2022-11-08 | $119.47M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $94.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $119.47M 10-Q · filed 2022-08-09 | $119.47M derived: sum of 3 quarters · filed 2022-08-09 | $119.47M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $25.00M 10-Q · filed 2022-05-09 | $25.00M derived: sum of 2 quarters · filed 2022-08-09 | $25.00M derived: sum of 3 quarters · filed 2022-08-09 | $25.00M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $0.00 derived: sum of 2 quarters · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2022-08-09 | $0.00 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |